| Literature DB >> 28373966 |
Leela K Bankapalli1, Rahul C Mishra1, Saumya Raychaudhuri1.
Abstract
VopE, a mitochondrial targeting T3SS effector protein of Vibrio cholerae, perturbs innate immunity by modulating mitochondrial dynamics. In the current study, ectopic expression of VopE was found to be toxic in a yeast model system and toxicity was further aggravated in the presence of various stressors. Interestingly, a VopE variant lacking predicted mitochondrial targeting sequence (MTS) also exhibited partial lethality in the yeast system. With the aid of yeast genetic tools and different stressors, we have demonstrated that VopE and its derivative VopEΔMTS modulate cell wall integrity (CWI-MAPK) signaling pathway and have identified several critical residues contributing to the lethality of VopE. Furthermore, co-expression of two effectors VopEΔMTS and VopX, interfering with the CWI-MAPK cellular pathway can partially suppress the VopX mediated yeast growth inhibition. Taken together, these results suggest that VopE alters signaling through the CWI-MAPK pathway, and demonstrates the usefulness of yeast model system to gain additional insights on the functionality of VopE.Entities:
Keywords: GAPs; MAPK signaling pathway; T3SS effector; Vibrio cholerae; stressors; suppression analysis; yeast mitochondria
Mesh:
Substances:
Year: 2017 PMID: 28373966 PMCID: PMC5357651 DOI: 10.3389/fcimb.2017.00082
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 5.293
Strains and plasmids used in this study.
| NovaBlue | Novagen | |
| DH5α | Microbial Type Culture Collection and Gene Bank (MTCC) | |
| SC110 | Non-O1/non-O139 strain of | Tripathi et al., |
| BY4741 | Bankapalli et al., | |
| BY4741 Δ | EUROSCARF | |
| BY4741 Δ | EUROSCARF | |
| BY4741 Δ | EUROSCARF | |
| BY4741 Δ | EUROSCARF | |
| BY4741 Δ | EUROSCARF | |
| BY4741 Δ | EUROSCARF | |
| BY4741 Δ | EUROSCARF | |
| BY4741 Δ | EUROSCARF | |
| BY4741 Δ | EUROSCARF | |
| BY4741 Δ | EUROSCARF | |
| BY4741 Δ | EUROSCARF | |
| BY4741 Δ | EUROSCARF | |
| BY4741 Δ | EUROSCARF | |
| BY4741 Δ | EUROSCARF | |
| BY4741 Δ | EUROSCARF | |
| BY4741 Δ | EUROSCARF | |
| BY4741 Δ | EUROSCARF | |
| BY4741 Δ | EUROSCARF | |
| W303-1A | Tripathi et al., | |
| pESCLEU | 2μ, | Agilent Technologies |
| pGML10 | RIKEN | |
| pAMU10 | RIKEN | |
| pRS413 | Gift from Dr. Deepak Sharma, Institute of Microbial Technology | |
| pESCLEU-VopE | 615 bp | This study |
| pESCLEU-VopER125A | VopE harboring A in place of R at position 125 | This study |
| pESCLEU-VopEΔ24−80 | VopE harboring deletion for 24–80 | This study |
| pESCLEU-VopEΔ1−80 | VopE harboring deletion for 1–80 | This study |
| pESCLEU-VopEΔMTS | VopE harboring deletion for 1–23 | This study |
| pESCLEU-VopEΔMTS R125A | VopE harboring deletion for 1–23, A in place of R at position 125 | This study |
| pESCLEU-VopEΔ119−121 | VopE harboring deletion for 119–121 | This study |
| pESCLEU-VopEΔ159−167 | VopE harboring deletion for 159–167 | This study |
| pESCLEU-VopEA120G | VopE harboring G in place of A at 120 | This study |
| pESCLEU-VopET129A | VopE harboring A in place of T at 129 | This study |
| pESCLEU-VopEQ161A | VopE harboring A in place of Q at 161 | This study |
| pESCLEU-VopEG163A | VopE harboring A in place of G at 163 | This study |
| pESCLEU-VopET164A | VopE harboring A in place of T at 164 | This study |
| pESCLEU-VopEF110A | VopE harboring A in place of F at 110 | This study |
| pESCLEU-VopEF162A | VopE harboring A in place of F at 162 | This study |
| pESCLEU-VopEV173A | VopE harboring A in place of V at 173 | This study |
| pESCLEU-mCherry | This study | |
| pESCLEU-VopE-mCherry | This study | |
| pESCLEU-VopER125A-mCherry | This study | |
| pESCLEU-VopEΔMTS-mCherry | This study | |
| pESCLEU-Gem1 | 1.99 kb | This study |
| pESCLEU-VopE-Gem1 | This study | |
| pESCLEU-VopX | This study | |
| pESCLEU-VopE-VopX | vopE ( | This study |
| pESCLEU-VopEΔMTS-VopX | This study | |
| pESCLEU-VopEΔMTS R125A-VopX | This study | |
| pGML10-VopE | 615 bp | This study |
| pAMU10-VopE | 615 bp | This study |
| pRS413-COX4-GFP | Amplified | This study |
| pKT760 | HOG 8x | Gift from Dr. Guido Sessa, Tel Aviv University, Israel |
| p1434 | CWI 2xRlm1- | |
| pMCZ | UPR, UPRE- | |
| Pheromone MAPK pathway Reporter plasmid | Pheromone, | |
Figure 1Effect of VopE on Yeast growth. (A) W303-1A transformants carrying VopE or VopER125A under control of GAL1 promoter were subjected to spotting on selective solid media containing glucose (repressor) or galactose (inducer). Liquid growth assay shown on right panel. Yeast harboring pESCLEU (high copy vector) treated as control. (B) Similar experiment was performed in BY4741 genetic background with pESCLEU cloning vector. (C) BY4741 transformants harboring pGML10 (low copy vector) or VopE were subjected to spotting under selective solid media containing glucose or galactose conditions. Liquid growth assay shown in (B) right panel. (D) For yeast growth viability analysis, BY4741 strains carrying VopE constructs were sampled at each time point and 10-fold serial dilutions were plated on glucose plate to count viable cells. Error bar indicates standard deviation from mean. Each experiment repeated three times with similar results.
Figure 2VopE Schematic representation of VopE domain or motif (B) BY4741 strains carrying pESCLEU or VopEΔMTS were spotted on solid selection media containing glucose or galactose (left panel). Same cultures also inoculated in liquid selection media containing galactose (right panel). (C) In vivo stability of VopE-3XFLAG and its derivatives confirmed by immunoblot using anti-FLAG antibody.
Figure 3Identification of residues and regions of VopE contributed in yeast toxicity. (A) Alignment of VopE along with other bacterial GTPase-activating protein sequences as carried out by Clustal Omega. Conserved and semi-conserved amino acid positions are highlighted with red and blue respectively. Predicted amino acids (*) involved in multiple interactions with unknown yeast target protein(s) or selected hydrophobic amino acids (▴) are substituted with alanine or glycine. The GenBank identifiers and species name are as follows: YopE [31795304|Yersinia pestis]; SptP[16421425|Salmonella typhimurium str. LT2]; VopE [254285224|Vibrio cholerae AM19226]; ExoS [450297| Pseudomonas aeruginosa]. (B) BY4741 cultures carrying a vector, either pESCLEU or VopE variants were 10-folded serial diluted and subjected to spotting on selective solid media containing glucose or galactose. (C) Expression of VopE-3XFLAG variants verified by western blot using anti-FLAG antibody.
Figure 4VopE targeted to yeast mitochondria and does not impair respiration. (A) Plasmids encoding mCherry or VopE-mCherry variants were introduced into yeast reporter strain BY4741-COX4-GFP. Mid-log phase cells were induced for 6 h by the addition of galactose. Mitochondria were visualized by COX4-GFP (targeting to mitochondrial matrix). Cells were examined by confocal laser scanning microscopy to monitor the localization patterns of VopE-mCherry constructs. Scale bar equals to 5 μm. (B) Detection of VopE-3XFLAG in mitochondrial fraction and whole cell lysate of 6 h galactose induced cultures with anti-FLAG antibody. Mitochondrial fraction was confirmed with anti-porin antibody. (C) BY4741 transformants expressing VopE either constitutive (pAMU10, low copy vector, top panel) or inducible (pESCLEU, high copy vector, bottom panel) were subjected to spotting on selective solid media containing glucose or 2% glycerol. For liquid growth induction, liquid cultures were pretreated with galactose for 6 h before spotting.
Figure 5Deletion or Over expression of Gem1 does not rescue yeast growth inhibition. 10-fold serial dilutions of (A) indicated BY4741 deletion strains containing eitheir pESCLEU or VopE (B) BY4741 transformants carrying either Gem1 alone or Gem1 and VopE, were subjected to spotting on selective solid media with glucose or galactose.
Figure 6Enhanced yeast toxicity under various stress conditions caused by VopE and VopE. Yeast growth inhibition phenotypes of (A) W303-1A transformants carrying either VopE or VopER125A (B) BY4741 transformants carrying VopE or its derivatives were examined by spotting on solid selection media containing galactose (inducing) plate without or with stressors. pESCLEU used as cloning vector. Stressors used in this experiment were as follows: Caffeine (3 mM), Tunicamycin (0.3 μg/ml), NaCl (0.5 M), Sorbitol (1 M), 37°C. Corresponding stressor sensitized BY4741 deletion strains (Δbck1, Δslt2, Δhog1, Δire1) were also spotted. Each experiment was repeated three times with similar results.
Figure 7Effect of VopE and VopE. Under inducing conditions, (A) BY4741 yeast strains harboring 2X-Rlm1 regulated lacZ reporter plasmid and VopE or its derivatives were treated with 3 mM caffeine for 4 h. VopE and VopEΔMTS significantly affect the activation of CWI-MAPK pathway. (B) Unfolded protein response was examined by incubating BY4741 transformants carrying UPRE regulated lacZ reporter plasmid and VopE or its derivatives in presence of 2 mM DTT for 4 h. VopE or VopEΔMTS greatly hampered activation of UPR response. (C) Activation of PFUS1-regulated lacZ reporter was also monitored for BY4741 transformants carrying reporter plasmid and VopE or its derivatives in response to 5 μM α-factor for 2 h. Reduced activation of pheromone MAPK pathway has been observed in the presence of VopE. (D) For HOG-MAPK pathway, W303-1A strains containing 8 × CRE-regulated lacZ reporter and VopE or its derivatives were incubated in the presence of NaCl (0.5 M) for 1 h. Activation of reporter activity was not effected. Error bar depict the standard deviation from mean of three independent clones. All experiments were repeated three times with similar results. For VopE and VopEΔMTS, an asterisk(s) indicates a statistically significant difference in mean values as compared to pESCLEU. For VopER125A, an asterisk(s) indicates a statistically significant difference in mean values as compared to VopE (*p < 0.05; **p < 0.001; ns-not significant; unpaired, two tailed student's t-test).
Figure 8Examination of VopE effect on CWI defective and metacaspase mutants. (A) BY4741Δbck1 and BY4741Δslt2 yeast deletion mutant strains showed increased yeast growth inhibition phenotype toward VopEΔMTS. (B) Over expression of VopE maintains toxicity in BY4741Δyca1 strain. All transformants were examined under solid selection media containing glucose or galactose. pESCLEU used as cloning vector.
Figure 9Expression of VopE BY4741 transformants carrying VopX and VopEΔMTS, VopX and VopEΔMTS R125A, or VopX and VopE were spotted on glucose and galactose plates. pESCLEU used as cloning vector for dual expression, where VopX and VopE variants cloned under GAL10 and GAL1 promoters, respectively.